Rune Nielsen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8521318/publications.pdf

Version: 2024-02-01

1040056 794594 32 392 9 19 citations h-index g-index papers 32 32 32 703 all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	The impact of COPD on health status: findings from the BOLD study. European Respiratory Journal, 2013, 42, 1472-1483.	6.7	83
2	Sex-related differences in respiratory symptoms: results from the BOLD Study. European Respiratory Journal, 2013, 42, 858-860.	6.7	37
3	Laboratory contamination in airway microbiome studies. BMC Microbiology, 2019, 19, 187.	3.3	31
4	Coagulation markers as predictors for clinical events in <scp>COPD</scp> . Respirology, 2021, 26, 342-351.	2.3	28
5	Risk factors for lung cancer in COPD – results from the Bergen COPD cohort study. Respiratory Medicine, 2019, 152, 81-88.	2.9	24
6	Excessive costs of COPD in ever-smokers. AÂlongitudinal community study. Respiratory Medicine, 2011, 105, 485-493.	2.9	22
7	Sputum microbiota and inflammation at stable state and during exacerbations in a cohort of chronic obstructive pulmonary disease (COPD) patients. PLoS ONE, 2019, 14, e0222449.	2.5	21
8	Determinants of fractional exhaled nitric oxide in healthy men and women from the European Community Respiratory Health Survey III. Clinical and Experimental Allergy, 2019, 49, 969-979.	2.9	19
9	Pharmacological treatment of asthma in a cohort of adults during a 20-year period: results from the European Community Respiratory Health Survey I, II and III. ERJ Open Research, 2019, 5, 00073-2018.	2.6	17
10	The airway microbiota and exacerbations of COPD. ERJ Open Research, 2020, 6, 00168-2020.	2.6	13
11	Exploring protocol bias in airway microbiome studies: one versus two PCR steps and 16S rRNA gene region V3 V4 versus V4. BMC Genomics, 2021, 22, 3.	2.8	11
12	Cost effectiveness of adding budesonide/formoterol to tiotropium in COPD in four Nordic countries. Respiratory Medicine, 2013, 107, 1709-1721.	2.9	9
13	Guideline adherence in hospital recruited and population based COPD patients. BMC Pulmonary Medicine, 2018, 18, 195.	2.0	9
14	Complications and discomfort after research bronchoscopy in the MicroCOPD study. BMJ Open Respiratory Research, 2020, 7, e000449.	3.0	9
15	Respiratory symptoms and mortality in four general population cohorts over 45 years. Respiratory Medicine, 2020, 170, 106060.	2.9	8
16	Chronic airflow obstruction and ambient particulate air pollution. Thorax, 2021, 76, 1236-1241.	5.6	7
17	Bronchodilator response and lung function decline: Associations with exhaled nitric oxide with regard to sex and smoking status. World Allergy Organization Journal, 2021, 14, 100544.	3.5	7
18	Aspects of healthcare utilisation in selfâ€reported obstructive lung disease. Clinical Respiratory Journal, 2009, 3, 34-41.	1.6	6

#	Article	IF	CITATIONS
19	Cryopreservation of osteo-chondral grafts in rabbits. Acta Orthopaedica, 1985, 56, 218-222.	1.4	5
20	Repeatability of health economic data in COPD. Respiratory Medicine, 2008, 102, 1556-1562.	2.9	5
21	Respiratory symptoms and respiratory deaths: A multi-cohort study with 45 years observation time. PLoS ONE, 2021, 16, e0260416.	2.5	5
22	Motivation and response rates in bronchoscopy studies. Multidisciplinary Respiratory Medicine, 2019, 14, 14.	1.5	4
23	Repeated bronchoscopy in health and obstructive lung disease: is the airway microbiome stable?. BMC Pulmonary Medicine, 2021, 21, 342.	2.0	4
24	The lower airways microbiome and antimicrobial peptides in idiopathic pulmonary fibrosis differ from chronic obstructive pulmonary disease. PLoS ONE, 2022, 17, e0262082.	2.5	4
25	Acute exacerbations of COPD and risk of lung cancer in COPD patients with and without a history of asthma. European Clinical Respiratory Journal, 2020, 7, 1799540.	1.5	2
26	A study of the airway mycobiome in COPD patients and controls. , 2019, , .		1
27	Factors associated with coronary heart disease in COPD patients and controls. PLoS ONE, 2022, 17, e0265682.	2.5	1
28	Predictors Of COPD Exacerbations In Hospital Patients, Population Based Cases And Controls., 2010,,.		O
29	Incremental costs of COPD exacerbations in GOLD stage 2+ COPD in ever-smokers of a general population. Respiratory Medicine: X, 2020, 2, 100014.	1.4	O
30	COPD phenotypes not linked to increased risk of coronary heart disease., 2019,,.		O
31	Bronchial wall inflammatory cells and signs of remodeling in COPD and asthma. , 2019, , .		O
32	Repeated bronchoscopy examination of the airway microbiome. , 2019, , .		0